Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors

Phase 2

Not yet recruiting

• Conditions: Nerve Sheath Tumor
• Interventions: Drug: FCN-159

• Registration Number: NCT06553365
• Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Brief Summary

The goal of this clinical trial is to evaluate the efficacy and safety of FCN-159 in patients with specific NF2-associated nerve sheath tumors.

Detailed Description

1. A phase 2 single arm single center study, total 30 patients will be enrolled;

2. To evaluate the safety and efficacy of FCN-159, a Mek inhibitor, to treat NF2; associated nerve sheath tumors, age≥16, including benign and malignant tumors;

3. Primary endpoint: Objective response rate (ORR)；Secondary Outcome Measures： Clinical benefit rate (CBR)；24w WRS, OS et al..

Study Timeline

• Status Verified: 2024-08
• Study First Submitted: 2024-08-03
• Study First Submitted QC: 2024-08-11
• Last Update Submitted: 2024-08-11
• Study First Posted: 2024-08-14
• Last Update Posted: 2024-08-14
• Study Start: 2024-08-15
• Primary Completion: 2026-07-31
• Study Completion: 2026-07-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. ≥16 years of age, regardless of gender.
2. meet the revised 2022 diagnostic criteria for NF2-associated nerve sheath tumors or pathologically confirmed NF2-associated nerve sheath tumors.
3. should meet one of the following criteria: 1) Incomplete surgical resection, or postoperative recurrence. 2) Systemic therapy is required as determined by the Investigator.
4. the presence of a measurable lesion, as defined by REiNS or RECIST V1.1 criteria.
5. Karnofsky physical status score of ≥70.
6. the patient has adequate organ and bone marrow function.
7. International Normalized Ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN.
8. For patients of childbearing potential: During treatment and for at least 90 days after the last dose, patients should agree to use a highly effective method of contraception.
9. avoid excessive sun exposure and be willing to use an adequate amount of sunscreen in anticipation of sun exposure.
10. be able to understand and voluntarily sign a written informed consent form.

Exclusion Criteria

• Previously received one of the following treatments:

  1. Pharmaceutical or biological therapy within 3 weeks or 5 half-lives prior to enrollment, whichever is longer.

  2. Use of growth factors that promote platelet, red blood cell, or white blood cell count or function within 7 days prior to enrollment.

  3. Patients who have received major surgery or anti-tumor immunotherapy within 4 weeks prior to enrollment.

  4. Radiation therapy for nerve sheath tumors within 4 weeks prior to enrollment.

  5. Dose adjustment for patients treated with dexamethasone or other corticosteroids within 1 week prior to enrollment.

  6. Patients who have participated in another interventional clinical trial within 4 weeks prior to enrollment.

  7. Prior treatment with Selumetinib or any other MEK 1/2 inhibitor. 2. history of or concurrent with other malignancies. 3. inability to undergo MRI and/or contraindications to MRI. 4. uncontrolled hypertension. 5. the presence of dysphagia, active gastrointestinal disease, malabsorption syndrome, or other condition that interferes with the absorption of the study medication.

     6. previous or current retinal vascular disease. 7. interstitial pneumonitis 8. cardiac function or co-morbidities 9. Immediate family history of sudden cardiac death before age 50. 10.History of any acute neurological condition 11. with active bacterial, fungal or viral infections 12. known hypersensitivity to the study drug, other MEK1/2 inhibitors, or their excipients.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
FCN-159	FCN-159	FCN-159 8mg qd po

Primary Outcome Measures

Name	Time	Method
Objective response rate (ORR) estimated by investigators	Every 4 cycles (each cycle is 28 days), assessed up to 2 years	Investigator-assessed objective mitigation rate ORR (Reponse evaluation in Nerufibromatosis and Schwannomatosis, REiNS criteria and RECIST 1.1 criteria, respectively)

Secondary Outcome Measures

Name	Time	Method
Clinical benefit rate (CBR) estimated by investigators	Every 4 cycles (each cycle is 28 days), assessed up to 2 years	Clinical benefit rate CBR will be assessed by the investigator (REiNS criteria and RECIST 1.1 criteria respectively)
24-week word recognition score (WRS)	up to 24 weeks	Hearing response changes will be assessed in patients with hearing impairment (24-week word recognition scores and pure tone audiometry).
pain estimated by NRS	Every 4 cycles (each cycle is 28 days), assessed up to 2 years	Change in pain intensity score relative to baseline will be assessed according to NRS scale.
Duration of response (DOR) assessed by investigator	From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years	Duration of response (DoR) is estimated by the investigators as the time from treatment initiation to disease progression or death in patients who achieve complete or partial response, using both RECIST V1.1 and REINS criteria.
progression free survival (PFS) assessed by investigator	From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years	PFS is estimated by the investigators as the time from treatment initiation to disease progression or death in patients, using both RECIST V1.1 and REINS criteria.